Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984
Recruiting
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: City of Hope National Medical Center, Duarte, California +121 locations
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847
Recruiting
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Arizona Arthritis & Rheumatology Research, PLLC, Sun City, Arizona +122 locations
Conditions: Primary Sjogrens Disease
Register for Updates
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT05744479
Recruiting
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD. Exercise and diet interventions have limitations and may not be sufficient, requiring effective adjunctive pharmacological approaches to target obesity and related comorbidities in IDD. However, persons with IDD treated... Read More
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
07/31/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Intellectual Disability, Developmental Disability, Obesity
Register for Updates
MRI Assessment of Pulmonary Edema in Acute Heart Failure
NCT03999138
Recruiting
Researchers are testing a more accurate way to measure how much fluid is in the lungs (also called pulmonary edema, or "increased lung water") in people with Heart Failure (HF) using MRI (Magnetic Resonance Imaging). There is little known about the exact level of lung water in patients with AHF or how these levels change from the time of hospital admission to discharge. The purpose of this research study is to measure the lung water in patients hospitalized for HF, to determine the change in lun... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Alberta, Edmonton, Alberta +1 locations
Conditions: Acute Heart Failure, Pulmonary Edema With Heart Failure
Register for Updates
Managing Impact-related Leakage During Exercise Using Intravaginal Support
NCT07103161
Recruiting
The goal of this study is to evaluate the effectiveness of using a regular menstrual tampon or a Uresta pessary to reduce urine leakage associated with running-induced stress urinary incontinence (RI-SUI) in females aged 18 and older. Secondly, the study aims to assess whether either intervention mitigates transient changes in pelvic morphology that occur following a single running bout. Lastly, we aim to evaluate whether participants continue using either intervention during running over the 4-... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Ottawa, Faculty of Health Sciences building, 200 Lees Avenue, Ottawa, Ontario
Conditions: Stress Urinary Incontinence (SUI)
Register for Updates
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT06388200
Recruiting
This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 150 subjects.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
07/31/2025
Locations: Associated Retina Consultants, Phoenix, Arizona +16 locations
Conditions: Retinitis Pigmentosa
Register for Updates
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
NCT04123795
Recruiting
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/31/2025
Locations: Ps0007 50214, Auburn, Alabama +50 locations
Conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Register for Updates
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357
Recruiting
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Research Site, Fairhope, Alabama +1017 locations
Conditions: Cardiovascular Disease
Register for Updates
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649
Recruiting
The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona +256 locations
Conditions: Metastatic Colorectal Cancer
Register for Updates
Feasibility of Choose to Move Replacement Ready
NCT07069179
Recruiting
Choose to Move (CTM) is a 3-month, choice-based health-promoting program for low active older adults being scaled-up across British Columbia (BC), Canada. Recently, the investigators adapted CTM for the \>14000 people in BC who are on surgical waitlists for total knee replacement or total hip replacement (TKR/THR) for osteoarthritis (OA). The primary goal of this observational study is to learn if the adapted program, Choose to Move Replacement Ready (CTM-RR), is feasible to deliver to people wi... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/30/2025
Locations: Active Aging Research Team, Robert H. N. Ho Research Centre, Vancouver, British Columbia
Conditions: Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoarthritis, Hip, Total Knee Arthroplasty; Total Hip Arthroplasty, Mobility Limitation, Social Isolation or Loneliness, Pain, Implementation Science, Physical Inactivity, Sedentary Behaviors
Register for Updates
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
Recruiting
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +34 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
AlloSure Lung Assessment and Metagenomics Outcomes Study
NCT05050955
Recruiting
ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama (UAB), Birmingham, Alabama +21 locations
Conditions: Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Register for Updates